Refine my results

Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using 149Tb-rituximab

Beyer, G.-J ; Miederer, M. ; Vranješ-Đurić, S. ; Čomor, J. ; Künzi, G. ; Hartley, O. ; Senekowitsch-Schmidtke, R. ; Soloviev, D. ; Buchegger, F.

In: European Journal of Nuclear Medicine and Molecular Imaging, 2004, vol. 31, no. 4, p. 547-554

Improving the chance of cure of follicular lymphoma by combining immunotherapy and radioimmunotherapy based on anti-CD20 antibodies?

Buchegger, F. ; Mach, J.-P ; Press, O. W. ; Bischof Delaloye, A. ; Larson, S. M. ; Prior, J. O. ; Ketterer, N.

In: Annals of Oncology, 2013, vol. 24, no. 7, p. 1948-1949

68Ga-NODAGA-RGDyK for αvβ3 integrin PET imaging : Preclinical investigation and dosimetry

Buchegger, F. ; Viertl, D. ; Baechler, Sébastien ; Dunet, V. ; Kosinski, M. ; Poitry-Yamate, C. ; Rüegg, Curzio ; Prior, J. O.

In: Nuklearmedizin, 2011, vol. 50, no. 6, p. 221-246

Aim: To visualize neovasculature and/or tumour integrin αvβ3 we selected the binding moiety Arg-Gly-Asp-D-Tyr-Lys (RGDyK) coupled to NODAGA for labeling with 68Ga. Methods: NODAGA-RGDyK (ABX) was labeled with the 68Ga eluate from the 68Ge generator IGG100 using the processor unit PharmTracer. Biodistribution was measured in female Hsd mice sacrificed 10, 30, 60 and 90 min after i.v. injection...